Biodesix, Inc. (BDSX)
| Market Cap | 102.29M |
| Revenue (ttm) | 88.50M |
| Net Income (ttm) | -35.27M |
| Shares Out | 10.11M |
| EPS (ttm) | -4.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,847 |
| Open | 10.33 |
| Previous Close | 10.13 |
| Day's Range | 10.12 - 10.33 |
| 52-Week Range | 3.44 - 20.21 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 32.50 (+221.15%) |
| Earnings Date | May 4, 2026 |
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to... [Read more]
Financial Performance
In 2025, Biodesix's revenue was $88.50 million, an increase of 24.08% compared to the previous year's $71.32 million. Losses were -$35.27 million, -17.86% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 221.15% from the latest price.
News
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarte...
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix ...
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing Includes novel proteomic and genomic approaches to ...
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,1...
Biodesix Transcript: Barclays 28th Annual Global Healthcare Conference
The company is expanding its lung diagnostics platform, leveraging genomics, proteomics, and radiomics to improve patient outcomes and operational efficiency. Strong sales growth, high gross margins, and a robust development pipeline support its focus on sustainable profitability and market expansion.
Biodesix Transcript: TD Cowen 46th Annual Health Care Conference
The company is expanding its lung diagnostics business, targeting both pulmonologists and primary care to address a large, underserved market. Strong real-world evidence, robust sales force productivity, and strategic partnerships support growth, while financial discipline and recent capital raises have strengthened the balance sheet.
Biodesix Earnings Call Transcript: Q4 2025
Q4 2025 saw 41% revenue growth and first-ever positive adjusted EBITDA, driven by lung diagnostics and expanded sales reach. 2026 guidance projects 23% revenue growth, with continued margin strength and operational leverage. Cash position strengthened by new financing and loan extension.
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-p...
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participat...
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quart...
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOU...
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ...
Biodesix Earnings Call Transcript: Q3 2025
Q3 2025 saw 20% revenue growth, improved gross margins, and strong expansion in primary care and development services. Raised full-year guidance to $84–$86 million, with Adjusted EBITDA positivity expected in Q4. Clinical and commercial momentum continues.
Biodesix Announces Third Quarter 2025 Results and Highlights
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 millio...
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific Speaker panel will...
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection...
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter...
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented One year after launch of real-world CLARIFY study, preliminary data from th...
Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit
Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients
Biodesix Announces One-for-Twenty Reverse Stock Split
LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock ...
Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1...
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncom...
Biodesix Transcript: Canaccord Genuity’s 45th Annual Growth Conference
The company is expanding its lung cancer diagnostic platform by integrating primary care referrals and growing its sales force, while digital ordering and biopharma partnerships drive operational and revenue gains. Ongoing clinical studies and collaborations with leading institutions support future growth and potential guideline inclusion.
Biodesix Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 12% year-over-year to $20M, driven by lung diagnostics and development services. Gross margin rose to 80%, and primary care test orders more than doubled. The company expects to reach adjusted EBITDA positivity in Q4, maintaining $80–$85M revenue guidance.
Biodesix Announces Second Quarter 2025 Results and Highlights
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 m...